Abstract
Development of molecular targeting agents, starting with imatinib for chronic myeloid leukemia or gefitinib for non-small cell lung cancer (NSCLC), has recently progressed at a rapid rate. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have already been developed to the 2nd and 3rd generation, and novel drug development targeted towards Met activation, which is an EGFR-TKI resistance mechanism, is ongoing. Although the era of new anticancer agents is moving towards an era of molecular targeting agents, the methods used for drug development are not different than before. In addition to the importance of pharmacokinetics (PK) and pharmacodynamics (PD) for drug development, emerging evidence is also demonstrating the significance of pharmacogenomics, since certain types of gene alteration may greatly affect drug metabolism, excretion, and notably, clinical efficacy. It is desirable to determine optimal doses of anticancer drugs by taking into account these factors that could potentially influence PK/PD. The following article reviews the clinical development of EGFR/Met inhibitors for NSCLC and the clinical pharmacology of these drugs.
Keywords: Epidermal growth factor receptor, Met, non-small cell lung cancer, pharmacology.
Current Drug Targets
Title:Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
Volume: 15 Issue: 14
Author(s): Shigehiro Yagishita and Akinobu Hamada
Affiliation:
Keywords: Epidermal growth factor receptor, Met, non-small cell lung cancer, pharmacology.
Abstract: Development of molecular targeting agents, starting with imatinib for chronic myeloid leukemia or gefitinib for non-small cell lung cancer (NSCLC), has recently progressed at a rapid rate. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have already been developed to the 2nd and 3rd generation, and novel drug development targeted towards Met activation, which is an EGFR-TKI resistance mechanism, is ongoing. Although the era of new anticancer agents is moving towards an era of molecular targeting agents, the methods used for drug development are not different than before. In addition to the importance of pharmacokinetics (PK) and pharmacodynamics (PD) for drug development, emerging evidence is also demonstrating the significance of pharmacogenomics, since certain types of gene alteration may greatly affect drug metabolism, excretion, and notably, clinical efficacy. It is desirable to determine optimal doses of anticancer drugs by taking into account these factors that could potentially influence PK/PD. The following article reviews the clinical development of EGFR/Met inhibitors for NSCLC and the clinical pharmacology of these drugs.
Export Options
About this article
Cite this article as:
Yagishita Shigehiro and Hamada Akinobu, Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/1389450115666141110154838
DOI https://dx.doi.org/10.2174/1389450115666141110154838 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development and Validation of a LC-MS/MS Method for Quantification of Mobocertinib (TAK-788) in Plasma and its Application to Pharmacokinetic Study in Rats
Combinatorial Chemistry & High Throughput Screening Lung Cancer Prediction Using Random Forest
Recent Advances in Computer Science and Communications Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Mini-Reviews in Medicinal Chemistry Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus
Current Proteomics Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells
Medicinal Chemistry Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Anticancer Activity of New Hydrazide-hydrazones and Their Pd(II) Complexes
Letters in Drug Design & Discovery Myeloid Derived Suppressor Cells and Their Role in Diseases
Current Medicinal Chemistry Biochemical and Pharmacological Applications of Essential Oils in Human Health Especially in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Diflunisal Thiazolidinones as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Curcumin: the Yellow Molecule with Pleiotropic Biological Effects
Letters in Drug Design & Discovery Exploration of Metastasis-related Proteins as Biomarkers and Therapeutic Targets in the Treatment of Head and Neck Cancer
Current Cancer Drug Targets Novel Hydroxamate and Anilide Derivatives as Potent Histone Deacetylase Inhibitors: Synthesis and Antiproliferative Evaluation
Current Medicinal Chemistry Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?
Current Medicinal Chemistry - Anti-Infective Agents In Vitro Inhibition Effect and Molecular Docking Study of Curcumin, Resveratrol, and Quercetin on Human Erythrocyte Glutathione Transferase
Current Enzyme Inhibition Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry